TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG Trademark

Trademark Overview


On Friday, November 13, 2020, a trademark application was filed for TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG with the United States Patent and Trademark Office. The USPTO has given the TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark a serial number of 90318619. The federal status of this trademark filing is REGISTERED as of Tuesday, October 5, 2021. This trademark is owned by Genentech, Inc.. The TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Providing online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to oncology, autoimmune, or inflammatory diseases
tecentriq atezolizumab injection for intravenous use 1200 mg

General Information


Serial Number90318619
Word MarkTECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG
Filing DateFriday, November 13, 2020
Status700 - REGISTERED
Status DateTuesday, October 5, 2021
Registration Number6506351
Registration DateTuesday, October 5, 2021
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 20, 2021

Trademark Statements


Description of MarkThe mark consists of THE WORD "TECENTRIQ" WITH "ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG" UNDER IT. THE FIRST "T" IN "TECENTRIQ" HAS THREE ARROWS POINTING INWARDS IN A CIRCLE ABOVE IT IN THE UPPER LEFT HAND CORNER.
Pseudo MarkTECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE TWELVE HUNDRED MILLIGRAMS; TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE ONE TWO ZERO ZERO MILLIGRAMS; TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE ONE THOUSAND TWO HUNDRED MILLIGRAMS
Goods and ServicesProviding online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to oncology, autoimmune, or inflammatory diseases
Disclaimer with Predetermined Text"ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG"

Classification Information


International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 13, 2021
Primary Code044
First Use Anywhere DateWednesday, May 18, 2016
First Use In Commerce DateWednesday, May 18, 2016

Trademark Owner History


Party NameGenentech, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameGenentech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Wednesday, April 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 5, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, July 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 20, 2021PUBLISHED FOR OPPOSITION
Wednesday, June 30, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 17, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 17, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 17, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 17, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 10, 2021NOTIFICATION OF PRIORITY ACTION E-MAILED
Monday, May 10, 2021PRIORITY ACTION E-MAILED
Monday, May 10, 2021PRIORITY ACTION WRITTEN
Thursday, April 22, 2021ASSIGNED TO EXAMINER
Monday, April 19, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, April 19, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 19, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, April 19, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 19, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 19, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, January 14, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, January 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 17, 2020NEW APPLICATION ENTERED